Abstract
INTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long-term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.
AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms - XIa and XIIa, respectively, within the intrinsic coagulation pathway. The authors examined data available on PubMed, Scopus, and the clinical trials registry of the United States National Library of Medicine (www.clinicaltrials.gov).
EXPERT OPINION: Therapies targeting factors XI or XII can yield anticoagulant efficacy with the potential to reduce adverse bleeding. Advantages for targeting factor XI or XII include a wider therapeutic window and reduced bleeding. Long-term follow-up studies and a greater understanding of the safety and efficacy are required. Atrial fibrillation is a chronic disease and therefore the development of oral formulations is key.
Original language | English |
---|---|
Journal | Expert Opinion on Investigational Drugs |
Volume | 30 |
Issue number | 10 |
Pages (from-to) | 1057-1069 |
Number of pages | 13 |
ISSN | 1354-3784 |
DOIs | |
Publication status | Published - Oct 2021 |
Keywords
- Anticoagulant
- antibody
- antisense oligonucleotide
- atrial fibrillation
- clinical trial
- clotting factor
- fxi
- fxii
- intrinsic pathway
- novel
- small molecule
- stroke
- therapeutics
- thromboembolism